NCT03755193RecruitingPhase 2
Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Source: ClinicalTrials.gov · Last updated 21 Sept 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 23 Nov 2018
- Start date
- 24 Nov 2018
- Primary completion date
- 23 Nov 2024
- Lead sponsor
- Shinshu University
- Diseases
- Osteoporosis
- NCT number
- NCT03755193
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 90
- From 24 Nov 2018 to the primary completion date, 23 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant
Who the study is looking for
- osteoporosis patients
Age in the registry: 20 years to 120 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yukio Nakamura Coordinator of this site? Confirm its status | Matsumoto | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.